Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zomedica Corp. ZOM

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.

Recent & Breaking News (NYSEAM:ZOM)

Zomedica CEO Interview with Wall Street Analyzer Discusses First Quarter 2022 Earnings and Future Plans

Accesswire May 16, 2022

Zomedica Announces First Quarter 2022 Revenues of $3.8 Million; 74% Gross Margin & $192.3 Million in Cash; Revenue up 38% from 2021 Combined Revenues

Accesswire May 10, 2022

Zomedica(R) Supports Feline Animal Health With American Association of Feline Practitioners' Sponsorship

Accesswire May 4, 2022

Zomedica to Present at H.C. Wainwright Global Investment Conference

Accesswire April 27, 2022

Zomedica's Announces Designation of Pulsevet System as the Official Shock Wave Therapy of the American Quarter Horse Association

Accesswire April 13, 2022

Zomedica Announces Launch of eACTH Assay for Truforma(R) Platform

Accesswire April 4, 2022

Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results

Accesswire March 1, 2022

Zomedica Announces Participation in the Q1 Virtual Investor Summit

Newsfile February 28, 2022

Zomedica Announces Fourth Quarter and 2021 Revenues of $4.1 Million; 73.9% Gross Margin

Accesswire February 25, 2022

Zomedica Appoints Adrian Lock to Lead Sales Organization

Accesswire February 15, 2022

Zomedica Announces Management Team Additions

Accesswire February 9, 2022

Zomedica Provides Updates on PulseVet Sales & Marketing Integration and Marketing Activities for the First Quarter of 2022

Accesswire January 27, 2022

Zomedica CEO Provides Update to Shareholders

Accesswire January 10, 2022

Zomedica to Present at H.C. Wainwright BioConnect 2022 Conference

Accesswire December 15, 2021

Zomedica Announces Third Quarter 2021 Financial Results

Accesswire November 12, 2021

SPAR Group Elects Mr. Sean M. Whelan and Mr. Michael Wager to its Board of Directors

GlobeNewswire October 21, 2021

Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan

GlobeNewswire October 4, 2021

Zomedica Acquires PulseVet

GlobeNewswire October 1, 2021

Sean Whelan Appointed to Board of Directors

GlobeNewswire September 13, 2021

Zomedica Announces Second Quarter 2021 Financial Results

GlobeNewswire August 11, 2021